SLC5A2 and hemorrhagic stroke: When only hemorrhagic stroke was included (this applied for the EMPA-RAG, CANVAS and CREDENCE trials), active treatment with SGLT2 inhibitors was associated with a significant 50% reduction (RR = 0.49, 95% CI 0.30–0.82, P = 0.007), with no evidence of heterogeneity between studies (I2 = 0%, P for interaction = 0.827; Fig. 3B).